Results 21 to 30 of about 900,797 (391)

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

open access: yes, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K.   +2 more
core   +2 more sources

Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues

open access: yesmAbs, 2020
The decision to pursue a monoclonal antibody (mAb) as a therapeutic for disease intervention requires the assessment of many factors, such as target-biology, including the total target burden and its accessibility at the intended site of action, as well ...
Kip P. Conner   +5 more
doaj   +1 more source

Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine During Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania. [PDF]

open access: yes, 2010
The combination of artemether (ARM) and lumefantrine is currently the first-line treatment of uncomplicated falciparum malaria in mainland Tanzania. While the exposure to lumefantrine has been associated with the probability of adequate clinical and ...
Annerberg, Anna   +10 more
core   +4 more sources

Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats

open access: yesPharmacology Research & Perspectives, 2020
The pharmacokinetics (PK), metabolism, excretion, mass balance, and tissue distribution of [14C]praliciguat were evaluated following oral administration of a 3‐mg/kg dose in Sprague‐Dawley rats and in a quantitative whole‐body autoradiography (QWBA ...
Ali R. Banijamali   +10 more
doaj   +1 more source

Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings

open access: yesMolecules, 2022
PSTi8 is a pancreastatin inhibitory peptide that is effective in the treatment of diabetic models. This study investigates the pharmacokinetic (PK) properties of PSTi8 in Sprague Dawley rats, for the first time.
Guru R. Valicherla   +8 more
doaj   +1 more source

Pharmacokinetics and population pharmacokinetics in pediatric oncology [PDF]

open access: yesPediatric Blood & Cancer, 2019
AbstractPharmacokinetic research has become increasingly important in pediatric oncology as it can have direct clinical implications and is a crucial component in individualized medicine. Population pharmacokinetics has become a popular method especially in children, due to the potential for sparse sampling, flexible sampling times, computing of ...
Sebastiaan D.T. Sassen   +3 more
openaire   +4 more sources

Personalizing HIV therapy, mission impossible? [PDF]

open access: yes, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

Artemisinins [PDF]

open access: yes, 2005
Artemisinins were discovered to be highly effective antimalarial drugs shortly after the isolation of the parent artemisinin in 1971 in China. These compounds combine potent, rapid antimalarial activity with a wide therapeutic index and an absence of ...
Haynes, RK, Krishna, S, Woodrow, CJ
core   +3 more sources

A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis

open access: yesCell Death Discovery, 2022
As the modulation of serine/arginine-rich splicing factor 3 (SRSF3) may be therapeutically beneficial to colorectal cancer (CRC) treatment, the identification of novel SRSF3 inhibitors is highly anticipated. However, pharmaceutical agents targeting SRSF3
Yawen Zhang   +14 more
doaj   +1 more source

Pharmacokinetics of Dasatinib [PDF]

open access: yesPrague Medical Report, 2019
Tyrosine kinase inhibitors have recently become an essential tool in management of chronic myeloid leukaemia (CML). Dasatinib, a representative of those drugs, acts by inhibiting key proteins included in CML development, predominantly Bcr-Abl and Src. Its advantage is that it shows activity in many cases where other agents bring no improvement due to ...
Jana Hořínková   +2 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy